Hyperthyroidism and Graves’ Disease
description
Transcript of Hyperthyroidism and Graves’ Disease
![Page 1: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/1.jpg)
HYPERTHYROIDISM AND
GRAVES’ DISEASE
Anthony Yin, MD
Sutter Pacific Medical FoundationDivision of Endocrinology, Diabetes and Osteoporosis
![Page 2: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/2.jpg)
• No financial disclosures
![Page 3: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/3.jpg)
CASE PRESENTATION
• 62 year old woman presents with fatigue and occasional palpitations for 3 months. Past medical history notable for long-standing hypertension and osteopenia based on a bone density study performed two years ago. She went through menopause at the age of 55 and has had no fractures. She has been an avid gardener for many years but has lost pleasure in this activity lately.
• She is a non smoker and only occasionally drinks alcohol. There is no family history of thyroid disease or malignancy
• Her medications are hydrochlorothiazide 25 mg/d, aspirin 81 mg/d, calcium 500 mg BID and vitamin D 800 IU/d
• No known medication allergies
![Page 4: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/4.jpg)
CASE PRESENTATION
• BP 135/82, HR 110, BMI 24• NAD, flat affect• No proptosis, lid lag or periorbital edema• Minimally enlarged smooth goiter with no palpable
nodules; bruits are present• CV: regular with occasional premature beats, no
murmurs• Mild tremor in both hands• Moderate khyposcoliosis without paravertebral
tenderness• No dermatologic abnormalities
![Page 5: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/5.jpg)
LABORATORY DATA
• CBC wnl• CMP notable for AST 62 and ALT 65 with
normal bilirubin and alkaline phosphatase
• 25-OH vit D3 is 22• TSH 0.03 (normal 0.45-4.5 uIU/mL), anti
TPO ab 22 (normal <35)• ESR 16
![Page 6: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/6.jpg)
QUESTIONS
• What is the differential diagnosis?• What further studies are
recommended?• How should she be treated?
![Page 7: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/7.jpg)
OUTLINE OF DISCUSSION
• What’s normal?• Scope of the Problem• Causes • Diagnostic Approach• Management
![Page 8: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/8.jpg)
WHAT’S NORMAL?
http://www.sciencedirect.com/science/article/pii/S0003986110002407
![Page 9: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/9.jpg)
SCOPE OF THE PROBLEM: HYPERTHYROIDISM• U.S.: prevalence 1.2%
- Overt 0.5%, 0.7% subclinical- Women 5x > men- More common in smokers
• Graves’ disease (GD) most common• Toxic multinodular goiter (TMNG) &
toxic adenoma (TA)
1. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 273:808–812.
2. 1Hollowell JG, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Heatlh and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489
3. Asvold BIO, et al. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167:1428.4. Holm IA, et al. Smoking and other lifestyle factors and the risk of Graves’ hyperthyroidism. Arch Intern Med 2005;
165:1606
![Page 10: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/10.jpg)
CLINICAL MANIFESTATIONS
• Anxiety• Emotional lability• Weakness• Tremor• Palpitations• Increased
perspiration• Weight loss (gain)• Normal or increased
appetite
![Page 11: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/11.jpg)
CLINICAL MANIFESTATIONS
• Anxiety• Emotional lability• Weakness• Tremor• Palpitations• Increased
perspiration• Weight loss (gain)• Normal or increased
appetite
• Hyperdefecation• Urinary frequency• Oligomenorrhea or amenorrhea
(women)• Gynecomastia and erectile
dysfunction (men)• New onset atrial fibrillation• Myopathy• Elderly patients may be
“apathetic”; depression
![Page 12: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/12.jpg)
STARE & LID LAG
http://www.patient.co.uk/doctor/Thyroid-Eye-Disease.htm
![Page 13: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/13.jpg)
EXOPHTHALMOSSPECIFIC TO GRAVES’ DISEASE
http://jnnp.bmj.com/content/75/suppl_4/iv2.full
http://www.myhousecallmd.com/archives/3761
Expected normal ranges:Caucasian males 12 - 21 mmCaucasian females 12 - 20 mmAfrican American males 12 - 24 mmAfrican American females 12 - 23 mm
http://www.opt.indiana.edu/riley/HomePage/External_Eye_Exam/Text_External_Eye_Exam.html
![Page 14: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/14.jpg)
GRAVES’ OPHTHALMOPATHY (GO)
• 50% of all with GD• 5% severe • Risk factors:
- radioiodine therapy for hyperthyroidism (318,319)
- smoking- high pretreatment T3 values (>325 ng/dL) (319)
- high serum pretreatment TRAb levels (>50% TBII inhibition or TSI >8.8 IU/Liter) (320)
- hypothyroidism following radioiodine treatment
![Page 15: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/15.jpg)
ACROPACHY & PRETIBIAL MYXEDEMA: SPECIFIC TO GRAVES’ DISEASE
http://jcem.endojournals.org/content/87/2/438/F1.expansion
http://see.visualdx.com/diagnosis/thyroid_acropachy
![Page 16: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/16.jpg)
CAUSES• GD• TMNG or TA• Thyroiditis• Iodine-induced
• Trophoblastic disease and germ cell tumors
• Extrathyroidal
![Page 17: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/17.jpg)
DIAGNOSTIC APPROACH
• Goiter + opthalmopathy + moderate to severe hyperthyroidism = GD
• Radioactive iodine uptake (RAIU)• Antibodies (TSI or TSH-R ab)• ESR (subacute thyroiditis)
![Page 18: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/18.jpg)
4 hour uptake 24 hour uptake Scan appearance
Graves’ disease
(Highly) Elevated
(Highly) Elevated
![Page 19: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/19.jpg)
4 hour uptake 24 hour uptake Scan appearance
Graves’ disease
(Highly) Elevated
(Highly) Elevated
Subacute, silent thyroiditis
Extremely low
(Typically not measured)
![Page 20: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/20.jpg)
4 hour uptake 24 hour uptake Scan appearance
Graves’ disease
(Highly) Elevated
(Highly) Elevated
Subacute, silent thyroiditis
Extremely low
(Typically not measured)
Autonomous nodule or toxic multinodular goiter
(Slightly) Elevated
(Slightly) Elevated
![Page 21: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/21.jpg)
4 hour uptake 24 hour uptake Scan appearance
Graves’ disease
(Highly) Elevated
(Highly) Elevated
Subacute, silent thyroiditis
Extremely low
(Typically not measured)
Autonomous nodule or toxic multinodular goiter
(Slightly) Elevated
(Slightly) Elevated
Exogenous hyperthyroidism
Low
![Page 22: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/22.jpg)
4 hour uptake 24 hour uptake Scan appearance
Graves’ disease
(Highly) Elevated
(Highly) Elevated
Subacute, silent thyroiditis
Extremely low
(Typically not measured)
Autonomous nodule or toxic multinodular goiter
(Slightly) Elevated
(Slightly) Elevated
Exogenous hyperthyroidism
Low
Euthyroidism Normal Normal
![Page 23: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/23.jpg)
GRAVES’ DISEASE (GD)
![Page 24: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/24.jpg)
TSI
![Page 25: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/25.jpg)
GD: TREATMENT
Medical Radioactive Iodine Surgery
![Page 26: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/26.jpg)
BETA BLOCKADE
PEARL:Beta-adrenergic blockade should be given to elderly patientswith symptomatic thyrotoxicosis and to other thyrotoxicpatients with resting heart rates in excess of 90 bpmor coexistent cardiovascular disease. RECOMMENDATION 2
![Page 27: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/27.jpg)
ANTI THYROID DRUGS (ATDS)
Methimazole(MMI)
Propylthiouracil(PTU)
![Page 28: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/28.jpg)
Cooper, David. Antithyroid Drugs. N Engl J Med352;9
![Page 29: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/29.jpg)
Cooper, David. Antithyroid Drugs. N Engl J Med352;9
![Page 30: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/30.jpg)
ANTI THYROID DRUGS (ATDS)Methimazole
(MMI)Propylthiouracil
(PTU)
• Initial dose: 10–20 mg/d• Maintenance dose:
generally 5–10 mg/d• Easier for patients• Side effects less
common• 15 mg/d $360/yr
• Initial dose: 300 mg/d• Preferred in
pregnancy• Higher potential for
side effects• 300 mg/d $408/yr Now only FDA
approved for treating hyperthyroidism during pregnancy
“should be used in virtually every patient who chooses antithyroid drug therapy for GD, except during the first trimester of pregnancy when propylthiouracil is preferred, in the treatment of thyroid storm, and in patients with minor reactions to methimazole who refuse radioactive iodine therapy or surgery”*RECOMMENDATION 13
![Page 31: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/31.jpg)
POSSIBLE SIDE EFFECTS
• pruritic rash• jaundice• acolic stools or dark urine• arthralgias• abdominal pain• nausea• fatigue• fever• pharyngitisRecommendation 14
![Page 32: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/32.jpg)
ANTI THYROID MEDICATIONS: TIMELINE & MONITORING
Start ATD
Week 0
![Page 33: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/33.jpg)
ANTI THYROID MEDICATIONS: TIMELINE & MONITORING
Start ATD
Week 4
q 4-8 week
sq 2-3
months
Week 0
Free T4 +T3
![Page 34: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/34.jpg)
ANTI THYROID MEDICATIONS: TIMELINE & MONITORING
Start ATD
Week 4
q 4-8 week
sq 2-3
months
Week 0
Free T4 +T3
12-18 month
s
Stop ATD
![Page 35: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/35.jpg)
ANTI THYROID MEDICATIONS: TIMELINE & MONITORING
Start ATD
Week 4
q 4-8 week
sq 2-3
months
Week 0
Free T4 +T3
12-18 month
s
Stop ATD
TSHFree
T4 T3
q 2 mo x 6 mo
![Page 36: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/36.jpg)
ANTI THYROID MEDICATIONS: TIMELINE & MONITORING
Start ATD
Week 4
q 4-8 week
sq 2-3
months
Week 0
Free T4 +T3
12-18 month
s
Remission?
Stop ATD
TSHFree
T4 T3
q 2 mo x 6 mo
No
I-131 ablation
No
TSHFree
T4 T3
q 12 mo
Yes
![Page 37: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/37.jpg)
• Radioactive Iodine Ablation
![Page 38: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/38.jpg)
ATDS GENERALLY NOT NECESSARY PRIOR TO 131I
• insufficient evidence for radioactive iodine worsening either the clinical or biochemical aspects of hyperthyroidism
• “it only delays treatment with radioactive iodine”
![Page 39: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/39.jpg)
PRETREATMENT MAY REDUCE THE EFFICACY OF SUBSEQUENT RADIOACTIVE IODINE THERAPY
Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, Fenzi GF, Pinchera A 1990 A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest 13:513–520
![Page 40: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/40.jpg)
WHEN TO USE MMI PRIOR TO 131I
- Risk for CV complications such as atrial fibrillation, heart failure, or pulmonary hypertension
- renal failure- infection- trauma- poorly controlled diabetes mellitus- cerebrovascular or pulmonary disease
If given as pretreatment, MMI should be discontinued 3–5 days before the administration of radioactive iodine, restarted 3–7 days later, and generally tapered over 4–6 weeks as thyroid function normalizes.
![Page 41: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/41.jpg)
GO: WORSENING WITH I-131
Traisk F, et al. Thyroid-Associated Ophthalmopathy after Treatmentfor Graves’ Hyperthyroidism with Antithyroid Drugsor Iodine-131. J Clin Endocrinol Metab 94: 3700–3707, 2009
![Page 42: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/42.jpg)
GO AND I-131: INCREASED PROPTOSIS
Traisk F, et al. Thyroid-Associated Ophthalmopathy after Treatmentfor Graves’ Hyperthyroidism with Antithyroid Drugsor Iodine-131. J Clin Endocrinol Metab 94: 3700–3707, 2009
![Page 43: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/43.jpg)
GO: EFFECTS OF I-131 AND SMOKING
Traisk F, et al. Thyroid-Associated Ophthalmopathy after Treatmentfor Graves’ Hyperthyroidism with Antithyroid Drugsor Iodine-131. J Clin Endocrinol Metab 94: 3700–3707, 2009
![Page 44: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/44.jpg)
RADIOACTIVE IODINE ABLATION: TIMELINE & MONITORING
I-131
Week 0
*Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011;364(6):542–50
**RECOMMENDATION 11***RECOMMENDATION 12
![Page 45: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/45.jpg)
RADIOACTIVE IODINE ABLATION: TIMELINE & MONITORING
I-131
Weeks 4-8
Week 0
Free T4 and T3
*Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011;364(6):542–50
**RECOMMENDATION 11***RECOMMENDATION 12
(expect normalization)
q 4-6 weeks**
![Page 46: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/46.jpg)
RADIOACTIVE IODINE ABLATION: TIMELINE & MONITORING
I-131
Weeks 4-8
Week 0
Free T4 and T3
6 months
No***
initiate LT4
Yes
*Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011;364(6): 542–50
**RECOMMENDATION 11***RECOMMENDATION 12
(expect normalization)
q 4-6 weeks**
Hypothyroid?
q6 weeks
TSH + free T4
![Page 47: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/47.jpg)
GD:TREATMENT
Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG,Taube A, Saaf M, Hamberger B 1996 Graves’ hyperthyroidism:treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J ClinEndocrinol Metab 81:2986–2993.
![Page 48: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/48.jpg)
GD:TREATMENT
Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG,Taube A, Saaf M, Hamberger B 1996 Graves’ hyperthyroidism:treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J ClinEndocrinol Metab 81:2986–2993.
![Page 49: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/49.jpg)
Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG,Taube A, Saaf M, Hamberger B 1996 Graves’ hyperthyroidism:treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J ClinEndocrinol Metab 81:2986–2993.
37%
6%21%
![Page 50: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/50.jpg)
CHOSING THERAPY
Radioactive iodine ablation
1. Females planning a pregnancy in the future > 4–6 months following RAI
2. Comorbidities increasing surgical risk3. Previous neck surgery or external radiation4. Lack of access to a high-volume thyroid
surgeon5. Contraindications to ATD use
• Pregnancy, lactation• Coexisting thyroid cancer, or suspicion cancer• Individuals unable to comply with radiation safety
guidelines• Women planning a pregnancy within 4–6 months
Thyroidectomy
![Page 51: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/51.jpg)
TSH, FT4/T3Eye findings+
goiter
Graves’ disease
Beta blockade
RAIU
PrednisoneYes
No
Active GO
TMNG or TA
Minimal
Elevated+
“hot” foci
Thyroiditis
Elevated, uniform
I-131 ablation Surgery
Consider patient preferences and comorbidities
MMI 10-20 mg/d
![Page 52: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/52.jpg)
PEARLS (TAKE-HOME MESSAGES FOR PRIMARY CARE PROVIDERS)
• ATDs• Methimazole is drug of choice; PTU only if
pregnant in 1st trimester Counsel on potential adverse reactions Baseline CBC, LFTs; routine monitoring
not formally recommended TSH not particularly helpful initially Allow 12-18 months to achieve remission
![Page 53: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/53.jpg)
PEARLS (TAKE-HOME MESSAGES FOR PRIMARY CARE PROVIDERS)
• RADIOACTIVE IODINE ABLATION• Contraindicated in pregnancy,
breastfeeding• Consider presence eye disease• Special diet and pretreatment with ATDs
usually not necessary and may make treatment less effective
• Takes several months to achieve therapeutic effect
TSH may remain low
![Page 54: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/54.jpg)
CASE DISCUSSION
• Graves’ disease• propranolol 20 mg TID • MMI 10 mg/d or I-131• If treated medically: free T4 and T3 now
and again in 4 weeks• Once euthyroid, monitor levels q3
months• Taper MMI after 12 months
![Page 55: Hyperthyroidism and Graves’ Disease](https://reader036.fdocuments.us/reader036/viewer/2022081419/568166f9550346895ddb5adc/html5/thumbnails/55.jpg)
QUESTIONS
• Thank you